Reflecting on the first half of 2025 including data from AACR, ASCO and EHA, we see several notable trends continuing to shape the oncology landscape. While development follows momentum observed the last few years, these learnings provide a…
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by…
On January 20, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under the Inflation Reduction Act (IRA). With the outcomes…
Introduction In the summer of 2023, many oncologists and cancer patients faced an impossible choice. Amidst many challenging treatment decisions, they had to determine how to proceed without two mainstays among oncology therapeutics: cisplatin and carboplatin. While it can…
Introduction The Trinity Life Sciences’ team recently attended the 65th ASH Annual Meeting and Exposition from December 9-12, 2023, in San Diego, California. The conference brought together physicians, scientists and industry experts to share and collaborate on advances in…
Executive Summary The Oncology Care Model (OCM) was designed to test whether financial incentives can improve care and lower Medicare (U.S. federal health insurance program) spending, emphasizing value-based care within oncology treatment. This model supported a wide range of…
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program…
Executive Summary Recent updates in the National Drug Reimbursement List (NRDL) have increasingly focused on the expansion of oncology products and highlighted the improving market access environment for innovative oncology therapies in China This effort first came under the…
Executive Summary The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years…
Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment. Key barriers for CAR T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare [...]